Japan Pharma Pandemic Impact: Win Some, Lose Some
Mix Varies By Company
Executive Summary
As Japanese pharma companies report quarterly results, the multi-faceted impact of the ongoing coronavirus pandemic on business operations has become clearer. The good news is that it’s been limited so far and the situation has been generally improving.
You may also be interested in...
AbbVie Eyes Japan Oncology Growth As Humira Biosimilar Looms
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.